---
title: "Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models | ERNA Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285379016.md"
description: "Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models | ERNA Stock News"
datetime: "2026-05-06T04:35:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285379016.md)
  - [en](https://longbridge.com/en/news/285379016.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285379016.md)
---

# Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models | ERNA Stock News

Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models | ERNA Stock News

### Related Stocks

- [ERNA.US](https://longbridge.com/en/quote/ERNA.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

- [Zydus buys US specialty drugmaker Assertio in Rs 1,600 crore all-cash deal](https://longbridge.com/en/news/286352725.md)
- [Artiva says AB-101 plus rituximab posts 71% ACR50 response in refractory RA study](https://longbridge.com/en/news/286959967.md)
- [Ernexa Therapeutics Stock Climbs On Breakthrough Preclinical Data](https://longbridge.com/en/news/285400985.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)